Sandeep Dhindsa, MD
Endocrinology, Diabetes & Metabolism · Saint Louis, MONPI 1881747301
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $29,425 of the $36,290 with a category attached, or 81.1%. 25 manufacturers reported payments, led by Acerus Pharmaceuticals Corporation at 26.2% of the total. 2025 is the largest year on record at $11,430, more than ten times the $563 reported in 2019.
Across 92 payments — averaging $394.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Acerus Pharmaceuticals Corporation$10K
- Tolmar, Inc.$8K
- Verity Pharmaceuticals Inc.$8K
- Clarus Therapeutics Inc.$5K
- Revvity, Inc.$3K
- Novo Nordisk$2K
- plus $2K from 19 others
Across 61 payments — averaging $2271.30 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$108K
- Regeneron$17K
- Novo Nordisk AS$14K
What the payments were for
- Consulting fees$1,3954%
- Speaking & faculty fees$29,42581%
- Travel & lodging$3,0358%
- Food & beverage$2,4357%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Acerus Pharmaceuticals Corporation | 9 | $9,523 |
| Tolmar, Inc. | 4 | $8,290 |
| Verity Pharmaceuticals Inc. | 4 | $7,636 |
| Clarus Therapeutics Inc. | 10 | $4,580 |
| Revvity, Inc. | 1 | $3,000 |
| Novo Nordisk | 6 | $1,505 |
| Amgen | 5 | $396 |
| Dexcom, Inc. | 12 | $197 |
| AstraZeneca | 4 | $168 |
| Abbott | 7 | $135 |
| Antares Pharma, Inc. | 1 | $130 |
| Radius Health, Inc. | 1 | $125 |
| Nevro Corp. | 2 | $119 |
| Boehringer Ingelheim | 7 | $114 |
| Medtronic(2 entities) | 3 | $75 |
| Lilly USA, LLC | 4 | $62 |
| Mannkind Corporation | 3 | $60 |
| Sanofi-aventis U.S. LLC | 2 | $33 |
| Sequel Med Tech, LLC | 1 | $31 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $24 |
| Insulet Corporation | 1 | $22 |
| AbbVie | 1 | $19 |
| Ascendis Pharma Endocrinology Inc | 1 | $19 |
| Shire North American Group Inc | 1 | $14 |
| Amryt Pharma Holdings Ltd | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$36,290 in reported general payments places this provider in the 85th percentile of 182 endocrinology, diabetes & metabolism providers in Missouri.
See all endocrinology, diabetes & metabolism providers in Missouri →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 209 | $315,570 |
| JardianceEmpagliflozin | 222 | $229,205 |
| MounjaroTirzepatide | 127 | $179,502 |
| TrulicityDulaglutide | 91 | $135,435 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 51 | $35,648 |
| FarxigaDapagliflozin Propanediol | 45 | $35,232 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 18 | $18,089 |
| JanuviaSitagliptin Phosphate | 16 | $15,724 |
| Tresiba Flextouch U-200Insulin Degludec | 13 | $15,478 |
| Tresiba Flextouch U-100Insulin Degludec | 16 | $14,878 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 35 | $14,623 |
| Testosterone | 100 | $13,338 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 84 | $11,401 |
| Humalog Kwikpen U-100Insulin Lispro | 36 | $9,796 |
| HumalogInsulin Lispro | 20 | $5,270 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Humalog, Insulin Lispro | $62 | $321,554253 claims |
| Novo NordiskOzempic | $1,505 | $315,570209 claims |
| Boehringer IngelheimJardiance | $114 | $229,205222 claims |
| AstraZenecaFarxiga | $168 | $35,23245 claims |
| AbbVieSynthroid | $19 | $1,06614 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 182 endocrinology, diabetes & metabolism providers in Missouri.
Other endocrinology, diabetes & metabolism in Saint Louis
- Janet McGillSaint Louis$212K
- Farid RomanSaint Louis$62K
- Kathryn DiemerSaint Louis$57K
- Julie SilversteinSaint Louis$49K
- Michael WhyteSaint Louis$40K
- Alexis McKeeSaint Louis$37K
- Thomas NickolasSaint Louis$35K
- K ThampySaint Louis$35K
- Garry TobinSaint Louis$30K
- Bharathi RajuSaint Louis$24K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.